

Biomarker Testing Market to Exceed USD 122.8 Billion by 2033 | DataM Intelligence

Biomarker Testing Market- Innovations in genomics, rising chronic disease incidence, and collaborative ventures propel global growth

AUSTIN, TX, UNITED STATES, June 4, 2025 /EINPresswire.com/ -- It is anticipated that the global <u>biomarker</u> <u>testing market</u> will experience rapid growth, with a valuation of approximately USD 122.8 billion by 2033, and a compound annual growth rate (CAGR) of 10.4% between 2025 and 2033. Biomarker tests, which are molecular indicators of health or



molecular indicators of health or illness, are becoming essential instruments for early detection, medication discovery, and

therapy monitoring as healthcare transitions to more personalized methods.

Download the sample Copy to explore key trends, innovations shaping the digital pills for mental

	-
6	6
-	-

In Japan, investing in Alzheimer's and regenerative biomarker research underscores our dedication to seniors and innovation, delivering earlier care." health market: <u>https://www.datamintelligence.com/download-</u> <u>sample/biomarker-testing-market</u>

Market Overview and Growth Drivers

The biomarker testing industry has experienced significant growth as a result of advancements in bioinformatics, proteomics, and genomics. Key growth drivers include:

DataM Intelligence

• Precision Medicine Adoption: In order to guarantee that

patients receive the most effective treatments possible, clinicians and researchers are increasingly utilizing biomarker testing to personalize medications, particularly in the context of cancer.

• Rising Chronic and Infectious Diseases: The significance of early and precise detection is

underscored by the increasing prevalence of infectious epidemics, Alzheimer's disease, cardiovascular issues, and cancer.

• Technological Innovations: High-throughput screening, multiplex assays, and next-generation sequencing systems have substantially reduced turnaround times and increased sensitivity, thereby making biomarker profiling more accessible.

• Regulatory Support: Clearer biomarker qualifying requirements have been published by the U.S. Food and Drug Administration (FDA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), which has facilitated the swifter adoption of these markers in the clinical setting.

• R&D Investments: In order to expedite the development of medications and prevent late-stage clinical trial failures, pharmaceutical and biotechnology companies are investing significantly in biomarker identification.

Regional Outlook

North America

The biomarker testing market is primarily dominated by North America, which accounts for approximately 40% of global sales. This leadership is predicated on a robust research infrastructure, significant healthcare expenditures, and the widespread utilization of companion diagnostics in the treatment of cancer. The region's pioneering significance is underscored by the ongoing conduct of large-scale biomarker-driven clinical studies by major university medical facilities and cancer institutes.

Europe

Europe has the second-largest proportion as a result of effective public-private partnerships. The Horizon Europe initiative of the European Union offers substantial funding for biomarker research in a variety of diseases, such as multiple sclerosis and breast cancer. Additionally, the rapid approval of biomarker assays is facilitated by the substantial regulatory support that firms receive in countries such as the United Kingdom, Germany, and France.

Asia-Pacific

The Asia-Pacific region is the fastest-growing category as a result of the expanded disposable income and enhanced healthcare facilities. Japan, China, and South Korea are initiating national genomics initiatives to integrate biomarker testing into standard healthcare. China, in particular, is making substantial investments in digital pathology systems and precision oncology laboratories, which are propelling market growth. Biomarker endpoints are also being adopted by India's expanding clinical trial sector in order to adhere to global standards.

Industry Momentum: Mergers, Partnerships, and Growth 2024–2025

As the biomarker testing space becomes more competitive, companies are forging alliances and executing mergers to enhance their technological capabilities and broaden geographic reach:

• Roche & Foundation Medicine (March 2024): Roche completed its acquisition of Foundation Medicine, strengthening its portfolio of genomic profiling assays and companion diagnostics.

• Thermo Fisher Scientific & QIAGEN (July 2024): Thermo Fisher formed a strategic partnership with QIAGEN to co-develop next-generation sequencing panels for rare disease biomarkers, leveraging Thermo Fisher's instrumentation and QIAGEN's assay expertise.

• Illumina & GRAIL (January 2025): Illumina finalized its merger with early cancer detection company GRAIL, integrating liquid biopsy technology to accelerate non-invasive cancer screening programs.

• Bio-Rad Laboratories & Pacific Biosciences (September 2024): Bio-Rad acquired Pacific Biosciences' high-accuracy sequencing module, aiming to enhance its digital PCR-based biomarker assays.

• Agilent Technologies & OncoDNA (February 2025): Agilent entered into a co-development agreement with European precision oncology firm OncoDNA to expand biomarker panels for personalized cancer treatment.

Competitive Landscape:

The major global players in the market include Merck KGaA, Abbott Laboratories, Thermo Fisher Scientific Inc., Q2 Solutions, IQVIA, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., Illumina, Inc., Labcorp Drug Development, Quanterix Corporation, and among others. Latest Developments

Beyond strategic consolidations, recent technological breakthroughs and real-world applications continue to reshape the market:

• Liquid Biopsy Advancements: Companies are developing blood-based diagnostics that are highly sensitive and can detect circulating tumor DNA (ctDNA). This technology enables the early diagnosis of recurrence and the minimum residual disease surveillance in cancer patients.

• Multiplex Proteomic Assays: The simultaneous measurement of hundreds of protein biomarkers is made possible by new mass-spectrometry-based technologies, which offer a more comprehensive understanding of neurodegenerative and cardiovascular diseases.

• Point-of-Care Biomarker Devices: The time to treatment is being reduced by testing handheld immunoassay readers for cardiac troponin and inflammatory markers in rural clinics and ambulances.

• Real-World Evidence Integration: Biotech businesses are collaborating with electronic health record (EHR) providers to improve biomarker validation for regulatory approval by correlating biomarker data to clinical outcomes.

Latest News from USA on Biomarker Testing Market:

The United States Centers for Medicare and Medicaid Services (CMS) announced in January 2025 that the payment for next-generation sequencing (NGS)-based biomarker testing across all cancer types will be increased. This will increase patient access to precision diagnostics. Simultaneously, the National Cancer Institute provided USD 75 million in funding to a team led

by Johns Hopkins University to verify a panel of early-detection biomarkers for pancreatic cancer. The objective of this initiative is to decrease the disease's notoriously late diagnosis rate.

Latest News from Japan on Biomarker Testing Market:

AMED (Japan Agency for Medical Research and Development) established the "Biomarker Innovation Program" in March 2025. The program aims to identify novel biomarkers for Alzheimer's disease and autoimmune ailments by investing USD 120 million over a five-year period. Additionally, Japan's commitment to translational research is illustrated by the establishment of a new clinical laboratory at Kyoto University's Center for iPS Cell Research, which is committed to the validation of pluripotent stem cell-derived tissue biomarkers for regenerative medicine applications.

Conclusion:

The biomarker testing industry is anticipated to experience accelerated growth as precision medicine becomes more incorporated into clinical processes. The integration of strategic collaborations, technological advancements, and supportive regulatory environments has rendered biomarker tests essential for the optimization of medications, diagnosis, and disease prevention. In order to fully actualize the potential of biomarker-driven healthcare, stakeholders, including diagnostic companies and healthcare providers, must continue to foster innovation and collaboration as the industry matures.

Gain expert insights on market trends, challenges, and future outlook. Buy the Full Report Now and strengthen your strategy with DataM Intelligence:

https://www.datamintelligence.com/buy-now-page?report=biomarker-testing-market

Stay informed with the latest industry insights-start your subscription now: <u>https://www.datamintelligence.com/reports-subscription</u>

Related Reports: <u>Cancer Biomarker Market growth expected to reach up to USD 32.5 bn by 2031</u>

Biomarkers market to grow at a CAGR of 11.9% during 2025-2032

Sai Kumar DataM Intelligence 4market Research LLP +1 877-441-4866 sai.k@datamintelligence.com Visit us on social media: LinkedIn X This press release can be viewed online at: https://www.einpresswire.com/article/818947463

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.